weekly_roundup
BioTechSign Daily Catalyst Roundup - November 12, 2026
Top BioTechSign catalyst names today: KURA, EYPT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 12, 2026
Daily Biotech Catalyst Digest: November 12, 2026
KURA leads the current BioTechSign screen at 86.6/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | 86.6 | A | publication signal 100%, clinical activity 100%, short interest 70% |
| EYPT | EyePoint, Inc. | 84.2 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| GRFS | Grifols SA | 74.8 | B | publication signal 100%, clinical activity 100%, dilution risk 19% |
| NKTR | Nektar Therapeutics | 74.4 | B | publication signal 100%, short interest 90%, clinical activity 75% |
| ARGX | argenx SE | 74.0 | B | publication signal 100%, clinical activity 100%, dilution risk 15% |
| NUVB | Nuvation Bio | 73.6 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
Recent Grade-Change Queue
- EYPT (EyePoint, Inc.) currently grades A with a 84.2/100 catalyst score. Main inputs: clinical activity 100%, short interest 70%, dilution risk 43%.
- UCBNV (UCB SA) currently grades F with a 12.5/100 catalyst score. Main inputs: clinical activity 12%.
- SNY (Sanofi SA) currently grades F with a 7.7/100 catalyst score. Main inputs: publication signal 100%, dilution risk 12%, short interest 10%.
- PBYI (Puma Biotechnology Inc) currently grades D with a 48.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, short interest 50%.
- EXEL (Exelixis Inc) currently grades F with a 27.4/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, clinical activity 29%.
- TARA (Protara Therapeutics, Inc. ) currently grades F with a 20.4/100 catalyst score. Main inputs: short interest 50%, dilution risk 35%, clinical activity 12%.
- CMPX (Compass Therapeutics, Inc.) currently grades C with a 52.5/100 catalyst score. Main inputs: short interest 90%, publication signal 60%, clinical activity 50%.
- BCAX (Bicara Therapeutics Inc.) currently grades F with a 24.8/100 catalyst score. Main inputs: short interest 70%, dilution risk 33%, publication signal 30%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.